Disease activity and multimorbidity among patients in the US with PsA varied based on geographic region, socioeconomic deprivation, race, and gender.

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Targeting prostate-specific membrane antigen, Lu-PSMA-617 has demonstrated clinical benefits in patients with PSMA-positive ...

Q3 2025 Earnings Call October 23, 2025 4:00 AM EDTCompany ParticipantsPascal Daloz - CEO & DirectorRouven Bergmann ...

The White House has confirmed that there are currently no plans for a meeting between US President Donald Trump and Russian ...

(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

From the Brat Pack to the Police Academy: 80s actors who shifted careers The 1980s created a generation of actors who became ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...